A case of severe ARDS in Adenovirus pneumonia successfully treated with Cidofovir: could lung ultrasound score be useful to guide and monitor antiviral treatment?

Dott. SANDRO PREGNOLATO (1), Dott.ssa SILVIA MONGODI (1), Dott.ssa GIULIA SALVE (1), Dott. ERMINIO SANTANGELO (2), Dott.ssa SILVIA BONAITI (1), Dott. ANDREA STELLA (1), Dott. ANDREA COLOMBO (1), Dott.ssa ANITA ORLANDO (1), Prof.ssa ROSANNA VASCHETTO (2), Prof. GIORGIO ANTONIO IOTTI (1), Prof. FRANCESCO MOJOLI (1)

Intensive Care Unit, Fondazione IRCCS Policlinico S. Matteo, University of Pavia, Pavia, Italia.
Intensive Care Unit, Ospedale Maggiore della Carità, University of Piemonte Orientale, Novara, Italia.

Argomento: Caso clinico

Background: Adenovirus HAdV-55 has been recently described to cause severe pneumonia in immunocompetent adults¹. There is no agreement about the adequate therapy, but some cases report Cidofovir efficacy². Lung ultrasound (LUS) is a bedside technique allowing ARDS assessment and monitoring³.

Aims and Objectives: To describe a case of immunocompetent 77-year-old man with severe ARDS caused by HAdV-55, treated with Cidofovir and monitored with LUS.

Case description: The patient was admitted to ICU with severe hypoxemia $(PaO_2/FiO_2=50 \text{ with} reservoire-bag mask)$, requiring intubation. Initial CT showed parenchymal consolidations in dependent areas, in right upper lobe and diffuse ground-glass opacities. LUS score was performed daily, examining 6 regions per hemithorax, each scored from 0 (normal) to 3 (complete consolidation). First global LUS score (obtained by the sum of regional scores) was 22. Empiric broad-spectrum antibiotics were started. Bronchoalveolar lavage, nasal swab and plasma resulted positive for HAdV-55. Despite esophageal-pressure guided protective mechanical ventilation, multiple cycles of prone positioning, toilette fiberbronchoscopy and iNO, 8 days later the patient was still severely hypoxemic, with higher HAdV's viral charge and a worsened LUS score (26). Off-label therapy with Cidofovir was administered (single dose-5mg/kg). Thereafter, we observed a progressive increase in PaO_2/FiO_2 ratio (from 54 to 270), with parallel reduction of LUS score (8)(Fig.1), as later confirmed by CT-scan. Viral samples required two weeks to show a reduction in HAdV-55 charge. The patient progressively improved and was finally discharged to a peripheral ICU while in weaning from mechanical ventilation.

Conclusions: Cidofovir for Adenovirus pneumonia is under discussion; LUS could integrate standard clinical and imaging assessment, allowing a daily reliable monitoring of aeration, helpful to decide to start and monitor the off-label, while reducing the need of CT.

References: 1.Narra, J Clin Virol.2016 2.Doan, Offic. Publ. Int. Soc. Heart Transplant.2007 3.Mojoli F, Am J Resp Crit Care Med.2018




Fig.1: Treand of lung ultrasound score, oxygenation and viral charge